AXN News 0.52 China Aoxing Pharmaceutical Company (AXN)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
China Aoxing Pharmaceutical Company (AXN) 0.52 $AXN

Aoxing Pharmaceutical Company, Inc. Receives Notice of Extension and Additional Notice of Noncompliance From NYSE MKT LLC
Marketwire - Tue Mar 04, 4:30PM CST
Aoxing Pharmaceutical Company, Inc. (NYSE MKT: AXN) ("Aoxing Pharma" , a specialty pharmaceutical company focusing on research, development, manufacturing, and distribution of narcotic, pain-management, and addiction treatment pharmaceuticals, announced on October 30, 2013 that it had received notice from NYSE MKT LLC that, based upon the financial statements contained in Aoxing Pharma's Annual Report on Form 10-K for the year ended June 30, 2013, Aoxing Pharma (a) is not in compliance with Section 1003(a)(iii) of the NYSE MKT Company Guide since it reported stockholders' equity of less than $6,000,000 at June 30, 2013 and has incurred losses from continuing operations and/or net losses in its five most recent fiscal years then ended, and (b) is not in compliance with Section 1003(a)(iv) of the Company Guide since it has sustained losses that are so substantial in relation to its overall operations or its existing financial resources, or its financial condition has become so impaired that it appears questionable, in the opinion of the NYSE MKT, as to whether the Company will be able to continue operations and/or meet its obligations as they mature. Aoxing Pharma further announced on December 4, 2013 that it had received notice from NYSE MKT LLC that, based upon the financial statements contained in Aoxing Pharma's Quarterly Report on Form 10-Q for the period ended September 30, 2013, Aoxing Pharma (a) is not in compliance with Section 1003(a)(ii) of the NYSE MKT Company Guide since it reported stockholders' equity of less than $4,000,000 at September 30, 2013 and has incurred losses from continuing operations and/or net losses in three of its four most recent fiscal years ended June 30, 2013.

Aoxing Pharmaceutical Company Inc posts lower net loss of USD1.918m for fiscal 2014 second quarter
M2 - Thu Feb 20, 9:06AM CST
Pharmaceutical company Aoxing Pharmaceutical Company Inc (NYSE MKT:AXN) on Wednesday reported a net loss of USD1.918m for its fiscal 2014 second quarter ended 31 December 2013.

Aoxing Pharmaceutical Company, Inc. Announces Financial Results for Second Quarter of 2014 Fiscal Year
Marketwire - Wed Feb 19, 11:15AM CST
Aoxing Pharmaceutical Company, Inc. (NYSE MKT: AXN) ("Aoxing Pharma" , a specialty pharmaceutical company focusing on research, development, manufacturing, and distribution of narcotic, pain-management, and addiction treatment pharmaceuticals, today announced its financial and operational results for the three and six month periods ended December 31, 2013. Complete financial results can be found in the Quarterly Report on Form 10-Q filed by Aoxing Pharma on February 19, 2014.

Why You Need to Pay Attention to Cambrex Corporation. (CBM) Stock? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Feb 10, 7:59AM CST
One company that should be on your radar is Cambrex Corporation that witnessed its Zacks Rank surge over the past four weeks, moving from Sell territory to its current position as a Strong Buy.

An Artful Way to Fight Dystonia
PR Newswire - Tue Jan 28, 7:30AM CST
Imagine a potentially debilitating neuromuscular disease that is relatively unknown, yet affects a half-million Americans of various ages, and, despite ongoing research, so far has no known cure. In addition, treatments are currently limited and carry significant side effects and risk. Would this qualify as a disease worthy of public awareness and continued research in the hopes of finding a cure? Thirteen-year-old entrepreneur Jared Shadkin believes that it is, and he is using the proceeds from the sale of his art to fund organizations dedicated to Dystonia awareness and research.

Aoxing Pharmaceutical Company, Inc. Receives Notice of Extension From NYSE MKT LLC
Marketwire - Wed Jan 15, 7:02AM CST
Aoxing Pharmaceutical Company, Inc. (NYSE MKT: AXN) ("Aoxing Pharma" , a specialty pharmaceutical company focusing on research, development, manufacturing, and distribution of narcotic, pain-management, and addiction treatment pharmaceuticals, announced on October 30, 2013 that it had received notice from NYSE MKT LLC that, based upon the financial statements contained in Aoxing Pharma's Annual Report on Form 10-K for the year ended June 30, 2013, Aoxing Pharma is not in compliance with Section 1003(a)(iii) of the NYSE MKT Company Guide since it reported stockholders' equity of less than $6,000,000 at June 30, 2013 and has incurred losses from continuing operations and/or net losses in its five most recent fiscal years then ended. On December 4, 2013, Aoxing Pharma announced that it had received additional notice from NYSE MKT LLC that, based upon the financial statements contained in Aoxing Pharma's Quarterly Report on Form 10-Q for the period ended September 30, 2013, it is also not in compliance with Section 1003(a)(ii) of the Company Guide since it reported stockholders' equity of less than $4,000,000 at September 30, 2013 and has incurred losses from continuing operations and/or net losses in three of its four most recent fiscal years ended June 30, 2013.

Biostar Pharmaceuticals, Inc. Announces the Designation of its PRC Operating Subsidiary as the Shaanxi Province Liver Disease Health Education Base
PR Newswire - Wed Jan 15, 7:00AM CST
Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) ("Biostar" or "the Company" , a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, today announced that its PRC operating subsidiary was designated as the Shaanxi Province Liver Disease Health Education Base.

Aoxing Pharmaceutical Company, Inc. Announces Financial Results for First Quarter of 2014 Fiscal Year
Marketwire - Thu Nov 14, 5:00PM CST
Aoxing Pharmaceutical Company, Inc. (NYSE MKT: AXN) ("Aoxing Pharma" , a specialty pharmaceutical company focusing on research, development, manufacturing, and distribution of narcotic, pain-management, and addiction treatment pharmaceuticals, today announced its financial and operational results for the quarter ended September 30, 2013. Complete financial results can be found in the Quarterly Report on Form 10-Q filed by Aoxing Pharma on November 14, 2013.

Aoxing Pharmaceutical Company, Inc. Receives Notice of Noncompliance From NYSE MKT LLC
Marketwire - Wed Oct 30, 4:57PM CDT
Aoxing Pharmaceutical Company, Inc. (NYSE MKT: AXN) ("Aoxing Pharma" , a specialty pharmaceutical company focusing on research, development, manufacturing, and distribution of narcotic, pain-management, and addiction treatment pharmaceuticals, today announced that it has received notice from NYSE MKT LLC that, based upon the financial statements contained in Aoxing Pharma's Annual Report on Form 10-K for the year ended June 30, 2013, Aoxing Pharma (a) is not in compliance with Section 1003(a)(iii) of the NYSE MKT Company Guide since it reported stockholders' equity of less than $6,000,000 at June 30, 2013 and has incurred losses from continuing operations and/or net losses in its five most recent fiscal years then ended, and (b) is not in compliance with Section 1003(a)(iv) of the Company Guide since it has sustained losses that are so substantial in relation to its overall operations or its existing financial resources, or its financial condition has become so impaired that it appears questionable, in the opinion of the NYSE MKT, as to whether the Company will be able to continue operations and/or meet its obligations as they mature. The notice advised that, in order to maintain its listing, Aoxing Pharma must submit a plan of compliance by November 8, 2013 addressing how it intends to regain compliance with Section 1003(a)(iv) by November 29, 2013, and must submit a plan of compliance by November 25, 2013 addressing how it intends to regain compliance with Section 1003(a)(iii) by April 27, 2015. If Aoxing Pharma fails to submit both plans or if the plans are not accepted, Aoxing Pharma will be subject to delisting proceedings.

OTC Signal Daily Stock Watch - Aoxing Pharmaceutical Company, Inc (NYSE: AXN)
WorldStockWire - Wed Sep 04, 4:45PM CDT
OTC Signal tracks stocks daily and is pleased to offer its stock alerts. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Signal at the following: http://www.otcsignal.com

Aoxing Pharmaceutical Company, Inc. Announces Financial Results For Third Quarter Of 2013 Fiscal Year
PR Newswire - Wed May 15, 3:21PM CDT
Aoxing Pharmaceutical Company, Inc. (NYSE MKT: AXN) ("Aoxing Pharma" , a specialty pharmaceutical company focusing on research, development, manufacturing, and distribution of narcotic, pain-management, and addiction treatment pharmaceuticals, today announced its financial and operational results for the three and nine month periods ended March 31, 2013. Complete financial results can be found in the Quarterly Report on Form 10-Q filed by Aoxing Pharma on May 15, 2013.

DAN, VRS, TEAR, AXN, DBB, OPTT Are Seasonally Ripe To Go Down In the Next Five Weeks
M2 - Tue May 14, 5:52AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Dana Holding Corp (NYSE AN), Verso Paper Corp (NYSE:VRS), Tearlab Corp (NASDAQ:TEAR), Aoxing Pharmaceutical Company Inc (AMEX:AXN), PowerShares DB Base Metals Fund (NYSE BB), Ocean Power Technologies Inc (NASDAQ:OPTT) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:

WEALTHMAKERS.COM Issues Bullish Research Reports on ADS, AXN, EGN, ETR, GABC, GTS
M2 - Fri Mar 29, 10:47AM CDT
WEALTHMAKERS.COM / www.wealthmakers.com , a Wall Street research and trading firm providing unbiased statistical stock market predictions to empower investors, securities professionals and public company employees to make precise, predictive and profitable trading decisions, has issued new research reports today on the following stocks: Alliance Data Systems Corp (NYSE:ADS), Aoxing Pharmaceutical Company Inc (AMEX:AXN), Engineeringcom Inc (NYSE:EGN), ENTERGY CORP (NYSE:ETR), German American Bancorp Inc (NASDAQ:GABC), Triple S Management Corp (NYSE:GTS)

Aoxing Pharmaceutical Company Inc reports net losses of USD3.136m for Q2 fiscal 2013
M2 - Tue Feb 19, 8:25AM CST
Pharmaceutical company Aoxing Pharmaceutical Company Inc (NYSE MKT:AXN) announced on Monday its net losses of USD3.136m for the three month period ended 31 December 2012.

Aoxing Pharmaceutical posts net loss of USD3.13m for Q2 fiscal 2013
M2 - Mon Feb 18, 6:48AM CST
Speciality pharmaceutical company Aoxing Pharmaceutical Company Inc (NYSE MKT: AXN) on Friday reported a net loss of USD3.135m for the second quarter of fiscal 2013, ended 31 December 2013.

Aoxing Pharmaceutical Company Inc's losses from operations widens to USD2.35m in Q2 fiscal 2013
M2 - Mon Feb 18, 6:39AM CST
Pharmaceutical company Aoxing Pharmaceutical Company Inc (NYSE MKT:AXN) stated on Friday its losses from operations of USD2.35m for the three month period ended 31 December 2012.

Aoxing Pharmaceutical Company, Inc. Announces Financial Results For Second Quarter Of 2013 Fiscal Year
PR Newswire - Fri Feb 15, 10:05AM CST
Aoxing Pharmaceutical Company, Inc. (NYSE MKT: AXN) ("Aoxing Pharma" , a specialty pharmaceutical company focusing on research, development, manufacturing, and distribution of narcotic, pain-management, and addiction treatment pharmaceuticals, today announced its financial and operational results for the three and six month periods ended December 31, 2012. Complete financial results can be found in the Quarterly Report on Form 10-Q filed by Aoxing Pharma on February 14, 2013.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Auria, LSAS Team Up: Japan Space Frontier Beckons

Updated Category News Views 105

Pioneering Ventures in Japan's Space Race Watch out, folks—Auria and LSAS Tec have something cooking. One's a titan in space technology, and the other's a maestro in mission analysis. They're joining forces to tango in Japan's booming space market. If you're into the street-smart equity dance, this partnership ain't just chatter over coffee; it's a leap toward new...

Continue Reading
De Beers Puts Namibia's 176-Carat Owishi on Display

Updated Category News Views 13

A 176-carat natural diamond can still make a room stop breathing, even in a trade battered by arguments over lab-grown supply, luxury spending, and what “rare” ought to mean anymore. De Beers Group, working with Grandview Klein Diamond, has unveiled Namibia’s Owishi natural diamond in Washington, DC. That is the hard fact on the table: a large Namibian stone, a U.S....

Continue Reading
ELEGOO's Formnext Push Tests a Broader 3D Ambition

Updated Category News Views 180

Frankfurt’s show floor is where product promises meet some very unforgiving eyeballs. ELEGOO arrived at Formnext 2026 with more than a refreshed machine or two: it is laying out a wider bet across resin printing, FDM printing, and 3D scanning. That matters because the company is no longer presenting itself as merely a supplier of affordable creator hardware. It wants to...

Continue Reading
Spruce Spins Adrenyx En Route to Nasdaq in 2027

Updated Category News Views 206

New Frontiers: Adrenyx Biosciences Takes Shape Well, here's a new chapter in biotech drama. Spruce Biosciences, a name you might have tangled with if you're into tickers like NASDAQ:SPRB, just carved out a niche with the birth of Adrenyx Biosciences. The play? A separate company eyeing the endocrinology space, setting its sights on tackling congenital adrenal hyperplasia...

Continue Reading
Boat Market Forecast Puts Services in the Driver’s Seat

Updated Category News Views 51

A jet ski is not exactly a sober economic indicator, yet the water is telling a useful story. MarketsandMarkets projects the global recreational boat market will rise from $31.38 billion in 2026 to $48.06 billion in 2033, a 6.3% compound annual growth rate. That is respectable growth for a costly discretionary category that got knocked around by softer purchasing activity...

Continue Reading
Aurora Innovation Faces Legal Probe After Stock Plunge

Updated Category News Views 182

Aurora's Troubles Draw Legal Scrutiny Looks like Aurora Innovation’s in the hot seat again, and not in a good way. When you see Kessler Topaz Meltzer & Check, LLP throwing their name into the mix, you know it’s getting serious. This legal eagle firm is poking around, seeing if Aurora stepped over the line with investors after their latest stumble—a production delay...

Continue Reading
Medical School Rejections Carry a Steep Price Tag Too

Updated Category News Views 107

A rejection letter can turn into a remarkably expensive piece of paper. BeMo Academic Consulting's new Medical School Admissions Trends Report argues that the damage from missing medical-school admission goes far beyond bruised confidence: applicants can spend thousands chasing another cycle, lose time entering practice, and, if they never get in, forgo what the report...

Continue Reading
Vertex Extends Genomics Pact With $220M in Potential

Updated Category News Views 54

Eight years is long enough to separate a useful science partner from a glossy slide deck, and Vertex’s decision to add four more years with Genomics deserves attention. This is not a splashy acquisition, nor is it a clean revenue number investors can plug into next quarter’s model. It is a deeper commitment to the slow, expensive, wonderfully unforgiving business of...

Continue Reading
AES Clears FERC, Nearing Its December 2 Takeover Close

Updated Category News Views 131

One more regulatory gate just swung open for AES, and this deal is finally staring at the finish line instead of wandering through the usual approval swamp. The Federal Energy Regulatory Commission has issued its final order approving AES's acquisition by a consortium led by Global Infrastructure Partners, part of BlackRock, and EQT Infrastructure VI. The last major...

Continue Reading
Madrigal Pharmaceuticals Faces Legal Scrutiny Over Data

Updated Category News Views 152

Legal Storm Brews for Madrigal Pharmaceuticals Watch out, here comes another storm for Madrigal Pharmaceuticals, folks. This ain't no small drizzle either; it's a full-on legal monsoon, and it's soaked straight through the walls of their executive suite. We're talking a whistleblower sending alarm bells ringing about data fudging and some dodgy boardroom maneuvers—as if...

Continue Reading

Top 5 Most Recently Viewed Articles

D.Law's New Office: A Major Step Forward in Growth

Updated Category News Views 158

D.Law Opens New Office in Glendale D.Law is excited to announce a significant milestone in its expansion with the launch of its new office at 450 N. Brand Blvd, Suite 840. This important development represents more than just a new location; it embodies the firm's dedication to growing its capabilities and providing better service to its clients. A New Beginning for D.Law...

Continue Reading
Innovative Hunting Shack Designed for Comfort and Covert Use

Updated Category News Views 155

Revolutionizing the Hunting Experience Hunting requires a blend of stealth, comfort, and practicality, all of which have inspired an exciting innovation: the specially designed hunting shack. An inventor focused on optimizing the hunting experience has created this remarkable mobile structure, ideal for outdoor enthusiasts seeking to enhance their hunting adventures. A...

Continue Reading
ALTA Honors Senate for Confirming Pulte as FHFA Director

Updated Category News Views 236

ALTA Celebrates Senate Confirmation of Bill Pulte The American Land Title Association (ALTA) has expressed its appreciation to the U.S. Senate following the confirmation of Bill Pulte as the new director of the Federal Housing Finance Agency (FHFA). This announcement marks a significant moment for both ALTA and the housing industry. Bill Pulte’s Role at FHFA Bill Pulte,...

Continue Reading
Celebrating Talar Guedikian's Achievement as Paralegal of the Year

Updated Category News Views 181

Talar Guedikian Named 2025 AAJ Paralegal of the Year The legal community is buzzing with excitement as Talar Guedikian, a dedicated Senior Litigation Paralegal, has been honored with the prestigious title of the 2025 AAJ Paralegal of the Year. This recognition, sponsored by Advocate Capital, showcases her exceptional capabilities and unwavering commitment to the legal...

Continue Reading
Bauer Hockey Welcomes Gillian Meek as New Executive Leader

Updated Category News Views 237

Bauer Hockey Appoints Gillian Meek as Executive Vice President Bauer Hockey, recognized globally as the leading manufacturer of hockey equipment and the premier brand within the sport, has made a significant executive change. The company has welcomed Gillian Meek as its new Executive Vice President and General Manager. This strategic move was announced recently, and it...

Continue Reading